Hot issues of immune checkpoint inhibitors in the treatment of non-small cell lung cancer
Immune checkpoint inhibitors(ICIs)is one of the important means to treat advanced non-small cell lung cancer(NSCLC)in clinic.More and more studies have begun to focus on drug resistance,immune related adverse events(irAEs)and biomarkers related to the prognosis of ICIs.Combined with recent research results,this work summarized the main applications of ICIs at this stage,the main mechanisms and treatment strategies of ICIs-related drug resistance,the related research progress of irAEs,and some potential prognostic biomarkers at this stage based on recent research results.
万方数据
维普
